Sorrento Therapeutics Inc.

NAS: SRNE

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 18, 2022, 7:57 p.m.

/zigman2/quotes/205669265/composite

$

4.24

Change

+0.01 +0.24%

Volume

Volume 40,306

Quotes are delayed by 20 min

/zigman2/quotes/205669265/composite

Previous close

$ 4.56

$ 4.23

Change

-0.33 -7.24%

Day low

Day high

$4.22

$4.53

Open

52 week low

52 week high

$4.22

$17.25

Open

Company Description

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular the...

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Valuation

Price to Sales Ratio

39.23

Price to Book Ratio

11.38

Enterprise Value to EBITDA

-8.71

Enterprise Value to Sales

31.71

Total Debt to Enterprise Value

0.10

Efficiency

Revenue/Employee

79,653.00

Income Per Employee

-594,544.00

Receivables Turnover

2.66

Total Asset Turnover

0.07

Liquidity

Current Ratio

0.89

Quick Ratio

0.87

Cash Ratio

0.59

Profitability

Gross Margin

51.68

Operating Margin

-503.99

Pretax Margin

-776.72

Net Margin

-746.41

Return on Assets

-49.06

Return on Equity

-244.90

Return on Total Capital

-63.61

Return on Invested Capital

-93.64

Capital Structure

Total Debt to Total Equity

102.57

Total Debt to Total Capital

50.63

Total Debt to Total Assets

28.29

Long-Term Debt to Equity

86.32

Long-Term Debt to Total Capital

42.61

Officers and Executives

Name Age Officer Since Title
Dr. Henry H. Ji 55 2006 Director & Chief Scientific Officer
Mr. Stephen L Klincewicz - 2017 VP-Pharmacovigilance & Clinical Operations
Mr. Najjam Asghar - 2019 Chief Accounting Officer
Dr. Mike A. Royal 66 2014 Chief Medical Officer
Dr. Shawn Sahebi - - Senior Vice President-Strategy & Analytics

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
09/29/2021 Henry H. Ji
See Remarks; Director
10,000   Derivative/Non-derivative trans. at $4 per share. 40,000
09/27/2021 Kim D. Janda
Director
42,357   Disposition at $8.02 per share. 339,703
09/27/2021 Kim D. Janda
Director
7,357   Derivative/Non-derivative trans. at $3.57 per share. 26,264
09/27/2021 Kim D. Janda
Director
35,000   Derivative/Non-derivative trans. at $1.8 per share. 63,000
09/13/2021 Kim D. Janda
Director
8,000   Disposition at $8.04 per share. 64,320
09/13/2021 Kim D. Janda
Director
8,000   Derivative/Non-derivative trans. at $3.5 per share. 28,000
09/03/2021 Robin L. Smith
Director
100,000   Derivative/Non-derivative trans. at $4.89 per share. 489,000
09/03/2021 Robin L. Smith
Director
75,000   Derivative/Non-derivative trans. at $3.95 per share. 296,250
04/12/2021 Kim D. Janda
Director
1,900   Disposition at $6.97 per share. 13,243
04/12/2021 Kim D. Janda
Director
1,900   Derivative/Non-derivative trans. at $3.5 per share. 6,650
03/16/2021 Najjam Asghar
Chief Financial Officer
56,974   Award at $0 per share. 0
12/16/2020 Dorman Followwill
Director
1,000   Disposition at $7.14 per share. 7,140
11/11/2020 Dorman Followwill
Director
1,000   0
03/05/2020 Robin L. Smith
Director
40,000   Acquisition at $2.27 per share. 90,800
09/13/2018 Ally Bridge Group HK Ltd
78,677   Disposition at $4.92 per share. 387,090
09/13/2018 Ally Bridge Group HK Ltd
29,137   Disposition at $5.01 per share. 145,976
/news/latest/company/us/srne

MarketWatch News on SRNE

  1. Sorrento Therapeutics says initial testing showed its COVISTIX test demonstrated ability to detect omicron variant

    9:25 a.m. Dec. 27, 2021

    - Tomi Kilgore

  2. Sorrento Therapeutics started at buy with $26 stock price target at B. Riley

    7:46 a.m. Jan. 29, 2021

    - Tomi Kilgore

  3. Charting market rotation, S&P 500 presses record territory

    12:40 p.m. Jan. 26, 2021

    - Michael Ashbaugh

  4. Charting market rotation, S&P 500 presses record territory

    12:16 p.m. Jan. 26, 2021

    - Michael Ashbaugh

  5. Sorrento stock falls after company fires CFO

    4:57 p.m. Aug. 18, 2020

    - Wallace Witkowski

  6. Sorrento Therapeutics started at buy with $24 stock price target at Dawson James Securities

    6:30 a.m. May 26, 2020

    - Tomi Kilgore

  7. America’s New Pastime: Day Trading

    8:40 a.m. May 23, 2020

    - Barron's Online

  8. Sorrento stock's intraday high of $10 was nearly 4 times Thursday's closing price

    1:39 p.m. May 18, 2020

    - Tomi Kilgore

  9. Sorrento Therapeutics' stock gains 1.9%, but pares earlier surge of as much as 48%

    1:38 p.m. May 18, 2020

    - Tomi Kilgore

  10. Stocks Rise Because There Is ‘No Limit’ to What Fed Can Do

    6:48 a.m. May 18, 2020

    - Barron's Online

  11. Sorrento Therapeutics' stock soars 44% premarket, after rocketing 158% on Friday

    6:30 a.m. May 18, 2020

    - Tomi Kilgore

  12. Loading more headlines...
/news/nonmarketwatch/company/us/srne

Other News on SRNE

  1. Calls grow to treat COVID like an 'endemic' illness

    3:52 a.m. Jan. 13, 2022

    - Seeking Alpha

  2. Sorrento's COVID-19 rapid antigen test detects Omicron variant

    9:29 a.m. Dec. 27, 2021

    - Seeking Alpha

  3. COVID-19 vaccine stocks surge on worries over new variant

    6:58 a.m. Nov. 26, 2021

    - Seeking Alpha

  4. Sorrento Therapeutics: COVISTIX Will Support The Growth

    1:33 a.m. Nov. 13, 2021

    - Seeking Alpha

  5. 10-Q: SORRENTO THERAPEUTICS, INC.

    4:48 p.m. Nov. 5, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  6. Loading more headlines...

At a Glance

Sorrento Therapeutics, Inc.

4955 Directors Place

San Diego, California 92121

Phone

1 8582034100

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$39.99M

Net Income

$-298.46M

2020 Sales Growth

27.2%

Employees

502.00

/news/pressrelease/company/us/srne

Press Releases on SRNE

  1. Anxious World Waits As Covid Vaccine Makers Address Omicron Variant

    8:50 a.m. Dec. 7, 2021

    - Financial News Media

  2. Anxious World Waits As Covid Vaccine Makers Address Omicron Variant

    8:45 a.m. Dec. 7, 2021

    - PR Newswire - PRF

  3. Loading more headlines...
Link to MarketWatch's Slice.